| Followers | 9 |
| Posts | 1597 |
| Boards Moderated | 1 |
| Alias Born | 01/27/2014 |
Thursday, February 16, 2017 10:46:07 AM
Exactech Schedules Fourth Quarter and Year-End 2016 Earnings Release and Conference Call
Exactech, an Arcam customer, will hold a conference call with CEO David Petty and key members of the management team on the same day, Tuesday, February 21 at 10:00 a.m. Eastern Time. The call will cover Exactech’s fourth quarter and year-end 2016 results. Petty will open the conference call and a question-and-answer session will follow. Something to fill the time until Arcam's Annual General Meeting on March 28th.
For what it's worth, the word "shareholder" is used 66 times in the 2015 EXACTECH ANNUAL REPORT
Exactech Schedules Fourth Quarter and Year-End 2016 Earnings Release and Conference Call - February 13, 2017
Exactech Expands Competency in 3-D Printing with Purchase of Arcam Q10plus Systems - June 16, 2016
Gainesville, Fla. (June 16, 2016) – Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic materials for extremities, knee, hip and spine, has confirmed the purchase of two Arcam Q10plus machines this week to expand its in-house manufacturing capabilities. This investment will advance Exactech’s long-term commitment to additive manufacturing technology, also known as 3-D printing.
“Integrating the Arcam Q10plus technology into our operations will bring numerous benefits to our already robust manufacturing systems,” said Raymond Cloutier, Exactech vice president of engineering & development for spine. “In 2010, Exactech became the first company to receive FDA clearance for a 3-D printed orthopaedic implant and has since received multiple additional clearances for other implants. We will now be able to leverage this knowledge and experience to enhance the design of our hip, knee, extremities and spine implants, reduce product development lead times and further supplement supply.”
The Arcam Q10plus is Arcam’s latest Electron Beam Melting (EBM) machine that has been designed specifically for cost-efficient production of orthopaedic implants. Studies have shown that build times can be reduced up to 25 percent with improved surface finishes, compared to previous generations of EBM systems.1
"Exactech was the first company in the U.S. to mass-produce medical implants using additive manufacturing. We are happy to see their confidence in our EBM technology and in the Arcam Q10plus as a volume production system for the medical device industry. We truly look forward to partnering with Exactech to grow production of their joint restoration products,” said Arcam Chief Executive Officer Magnus René.
“This equipment supports our long-range commitment to additive manufacturing, our comprehensive effort to optimize our supply chain and our perpetual interest in cost reduction,” said Exactech Chief Financial Officer Jody Phillips.
A page from the Exactech Corporate PowerPoint Presentation (August 2016), part of the Investors ? Shareholder Services ? Online Investor Kit
Exactech Corporate Orientation Published on Sep 23, 2016
Florida Gators: Exactech Arena Announcement Published on Jun 9, 2016
Exactech Employees Like to Move, Move, Move
About Arcam
WELCOME TO ARCAM´S INVESTOR RELATIONS INFORMATION!
Arcam strives to provide open and clear information to present and potential shareholders as well as other stakeholders and media.It is important for us that the information we give makes it possible to correctly understand the company´s present situation as well as its future potential.
Some documentation, like by-laws and protocols from general meetings are provided in Swedish only. Should you wish information beyond what is available on this site please do not hesitate to contact us.
We publish important information as well as press releases.
Arcam’s ambition is to communicate information internally and externally so that information about the company and its operations, as well as confidence in the company, is maintained. The information must be correct, relevant and well-formulated as well as adapted to the target groups, including shareholders, the capital market, media, employees, suppliers, customers, authorities and the public.
Arcam complies with the rules for disclosure of information established in the NASDAQ Stockholm regulations for issuers. The company makes public business events that the company considers to be critical and that may affect the price. Orders with a value exceeding MSEK 20 will always be made public.
Exactech, an Arcam customer, will hold a conference call with CEO David Petty and key members of the management team on the same day, Tuesday, February 21 at 10:00 a.m. Eastern Time. The call will cover Exactech’s fourth quarter and year-end 2016 results. Petty will open the conference call and a question-and-answer session will follow. Something to fill the time until Arcam's Annual General Meeting on March 28th.
For what it's worth, the word "shareholder" is used 66 times in the 2015 EXACTECH ANNUAL REPORT
Exactech Schedules Fourth Quarter and Year-End 2016 Earnings Release and Conference Call - February 13, 2017
Exactech Expands Competency in 3-D Printing with Purchase of Arcam Q10plus Systems - June 16, 2016
Gainesville, Fla. (June 16, 2016) – Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic materials for extremities, knee, hip and spine, has confirmed the purchase of two Arcam Q10plus machines this week to expand its in-house manufacturing capabilities. This investment will advance Exactech’s long-term commitment to additive manufacturing technology, also known as 3-D printing.
“Integrating the Arcam Q10plus technology into our operations will bring numerous benefits to our already robust manufacturing systems,” said Raymond Cloutier, Exactech vice president of engineering & development for spine. “In 2010, Exactech became the first company to receive FDA clearance for a 3-D printed orthopaedic implant and has since received multiple additional clearances for other implants. We will now be able to leverage this knowledge and experience to enhance the design of our hip, knee, extremities and spine implants, reduce product development lead times and further supplement supply.”
The Arcam Q10plus is Arcam’s latest Electron Beam Melting (EBM) machine that has been designed specifically for cost-efficient production of orthopaedic implants. Studies have shown that build times can be reduced up to 25 percent with improved surface finishes, compared to previous generations of EBM systems.1
"Exactech was the first company in the U.S. to mass-produce medical implants using additive manufacturing. We are happy to see their confidence in our EBM technology and in the Arcam Q10plus as a volume production system for the medical device industry. We truly look forward to partnering with Exactech to grow production of their joint restoration products,” said Arcam Chief Executive Officer Magnus René.
“This equipment supports our long-range commitment to additive manufacturing, our comprehensive effort to optimize our supply chain and our perpetual interest in cost reduction,” said Exactech Chief Financial Officer Jody Phillips.
A page from the Exactech Corporate PowerPoint Presentation (August 2016), part of the Investors ? Shareholder Services ? Online Investor Kit
Exactech Corporate Orientation Published on Sep 23, 2016
Florida Gators: Exactech Arena Announcement Published on Jun 9, 2016
Exactech Employees Like to Move, Move, Move
About Arcam
WELCOME TO ARCAM´S INVESTOR RELATIONS INFORMATION!
Arcam strives to provide open and clear information to present and potential shareholders as well as other stakeholders and media.It is important for us that the information we give makes it possible to correctly understand the company´s present situation as well as its future potential.
Some documentation, like by-laws and protocols from general meetings are provided in Swedish only. Should you wish information beyond what is available on this site please do not hesitate to contact us.
We publish important information as well as press releases.
Arcam’s ambition is to communicate information internally and externally so that information about the company and its operations, as well as confidence in the company, is maintained. The information must be correct, relevant and well-formulated as well as adapted to the target groups, including shareholders, the capital market, media, employees, suppliers, customers, authorities and the public.
Arcam complies with the rules for disclosure of information established in the NASDAQ Stockholm regulations for issuers. The company makes public business events that the company considers to be critical and that may affect the price. Orders with a value exceeding MSEK 20 will always be made public.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
